| Literature DB >> 30819895 |
Hailan Meng1,2,3,4,5, Haoran Zhao1,2, Xiang Cao1,2,3,4,5, Junwei Hao6, He Zhang1,2,3,4,5, Yi Liu1,2,3,4,5, Min-Sheng Zhu7,8, Lizhen Fan1,2, Leihua Weng1,2, Lai Qian1,2,3,4,5, Xiaoying Wang9, Yun Xu10,2,3,4,5.
Abstract
CD3+CD4-CD8- T cells (double-negative T cells; DNTs) have diverse functions in peripheral immune-related diseases by regulating immunological and inflammatory homeostasis. However, the functions of DNTs in the central nervous system remain unknown. Here, we found that the levels of DNTs were dramatically increased in both the brain and peripheral blood of stroke patients and in a mouse model in a time-dependent manner. The infiltrating DNTs enhanced cerebral immune and inflammatory responses and exacerbated ischemic brain injury by modulating the FasL/PTPN2/TNF-α signaling pathway. Blockade of this pathway limited DNT-mediated neuroinflammation and improved the outcomes of stroke. Our results identified a critical function of DNTs in the ischemic brain, suggesting that this unique population serves as an attractive target for the treatment of ischemic stroke.Entities:
Keywords: DNTs; FasL; T cell-mediated immunity; ischemic stroke; neuroinflammation
Mesh:
Substances:
Year: 2019 PMID: 30819895 PMCID: PMC6431175 DOI: 10.1073/pnas.1814394116
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205
Fig. 1.Levels of DNTs increased in the brain and blood of stroke patients and MCAO mice. (A) Representative FACS plots of CD3+CD4−CD8− T cells (DNTs) in the blood of 47 stroke patients and 33 healthy controls. Con, control. (B) The percentages of DNTs, CD4+ T cells, and CD8+ T cells in human blood. (C) Confocal images of brain sections from stroke patients. (Scale bars, 20 µm.) The arrows indicate CD3+CD4−CD8− T cells in brain slices. n = 10 sections from six stroke patients. (D) Quantitation of CD4+ T cells, CD8+ T cells, and DNTs surrounding microglia in brains of stroke patients. We quantified 36 fields in 6 samples and counted 105 microglia in ischemic penumbra (Upper) and random fields (Lower). Blue sectors indicate percentages of the T cell subset around microglia. (E and F) The numbers and percentages of CD4+ T cells, CD8+ T cells, and CD4−CD8− T cells over the CD3+ T cell population in the mouse ischemic hemisphere 1 and 3 d after MCAO evaluated by FACS (n = 10 per group). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the sham group. n.s., not significant. The data are presented as the mean ± SD.
Fig. 2.DNTs promoted proinflammatory microglial activation during ischemic stroke. (A) Flow cytometry analysis of the percentages of CD11b+CD45midCD86+ proinflammatory and CD11b+CD45midCD206+ antiinflammatory microglia. (B) RT-PCR results showing the mRNA levels of the proinflammatory surface marker CD86 and the antiinflammatory surface marker CD206 in the ipsilateral cortex. (C) Images of the cortex costained for CD86 (green) and Iba-1 (red) or for CD206 (green) and Iba-1 (red). (Scale bar, 50 µm.) (D) The percentages of CD86+/Iba-1+ cells and CD206+/Iba-1+ cells are quantified. n = 10 animals per group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the sham group. (E) DNTs (5 × 105 cells) sorted from the spleens of C57BL/6J mice 3 d after MCAO were cocultured with microglia (5 × 105 cells) for 24 h. The percentages of CD86+ and CD206+ microglia were analyzed by flow cytometry. (F) RT-PCR results showing the mRNA levels of proinflammatory markers (CD16 and CD86) and antiinflammatory markers (Arg-1 and CD206). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the microglia (MG) group. The data are presented as the mean ± SD. M1d, day 1 of MCAO; M3d, day 3 of MCAO.
Fig. 3.Rag1−/− mice reconstituted with DNTs with a FasL mutation showed reduced brain injury and microglial inflammation. (A and B) TTC staining showing the infarct volume in Rag1−/− mice receiving DNTs from C57BL/6J or gld mice 3 d after MCAO. (C–E) Neurological severity scores, corner test, and rotarod test in the indicated mice after MCAO. (F and G) Representative images and quantification of the cortex CD86+/Iba-1+ and CD206+/Iba-1+ microglia in the ischemic hemisphere. (Scale bar, 50 µm.) n = 10 animals per group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the Rag1−/− mice with MCAO; &P < 0.05, &&P < 0.01, and &&&P < 0.001 compared with Rag1−/− mice reconstituted with B6 DNTs. The data are presented as the mean ± SD.
Fig. 4.DNT-derived TNF-α promoted proinflammatory microglial activation. The CM was collected from the cultured DNTs sorted from the spleens of C57BL/6J mice with or without MCAO and used to stimulate microglia for 24 h. (A) The percentages of CD86+ proinflammatory and CD206+ antiinflammatory microglia were determined using FACS. n = 12 animals per group. *P < 0.05 and **P < 0.01 compared with the control group (microglia only). (B and C) The cytokine profiles in the DNT CM before and after MCAO were evaluated by CBA. n = 12 animals per group. *P < 0.05 and ***P < 0.001 compared with the B6 CM (without MCAO) group. (D) The microglia were treated with or without TNF-α at two concentrations. The percentages of CD86+ proinflammatory and CD206+ antiinflammatory microglia were determined using FACS. n = 12 samples per group. *P < 0.05 and **P < 0.01 compared with the control group (without TNF-α); &P < 0.05 and &&P < 0.01 compared with the 50 pg/mL TNF-α–stimulated group. (E) CM from DNTs treated with or without the TNF-α inhibitor lenalidomide (5 µM) was applied to microglia. The percentages of CD86+ and CD206+ microglia were determined using FACS. n = 12 samples per group. **P < 0.01 compared with the control group (without DNT supernatant or lenalidomide); &&P < 0.01 compared with the DNT supernatant-stimulated group. The data are presented as the mean ± SD.
Fig. 5.FasL deficiency inhibited TNF-α secretion from DNTs and attenuated proinflammatory microglial activation after stroke. (A and B) Representative FACS plots and quantification of CD4−CD8− T cells in the brain 1 and 3 d after MCAO. (C and D) Images and quantification of cortex CD86+/Iba-1+ microglia. (Scale bar, 50 µm.) n = 10 animals per group. (E and F) Images and quantification of cortex CD206+/Iba-1+ microglia. (Scale bar, 50 µm.) n = 10 animals per group. &P < 0.05 and &&P < 0.01 compared with the B6 MCAO group. DNTs obtained from C57BL/6J and gld mice 3 d after MCAO were cultured in vitro for 24 h. The DNT supernatant was collected and used to stimulate microglia for 24 h. (G) The cytokine profiles of the DNT supernatant were evaluated using CBA. (H) The percentages of CD86+ and CD206+ microglia were analyzed using FACS. n = 12 samples per group. *P < 0.05 and **P < 0.01 compared with the control group (microglia only); &&P < 0.01 and &&&P < 0.001 compared with the B6 group. The data are presented as the mean ± SD. M1d, day 1 of MCAO; M3d, day 3 of MCAO.
Fig. 6.Verification of differentially expressed inflammatory proteins identified in the proteomic analysis. Mass spectrometry was used to profile the global alterations in proteins expressed in DNTs isolated from B6 and gld mouse spleens 3 d after MCAO. (A) The Venn diagrams show that 127 proteins were up-regulated after MCAO, and the changes were reversed by the FasL mutation in gld mice. (B) Three hundred thirty-eight proteins were down-regulated after MCAO and rescued by the FasL mutation in gld mice. (C) RT-PCR analysis of four proinflammatory proteins (S100A9, S100A8, TIAL1, and RFTN1) and five antiinflammatory proteins (GPS1, SH3KBP1, PTPN2, C1QBP, and LPXN) in DNTs of the indicated mice. n = 9 mice per group. **P < 0.01 compared with the B6 sham group; &P < 0.05 and &&P < 0.01 compared with the B6 MCAO 3-d group. (D) Representative Western blots and quantification for PTPN2 and TIAL1. n = 9 samples per group. **P < 0.01 compared with the B6 sham group; #P < 0.05 compared with the gld sham group; &P < 0.05 compared with the B6 MCAO 3-d group. The data are presented as the mean ± SD. M1d, day 1 of MCAO; M3d, day 3 of MCAO.
Fig. 7.TNF-α expression is negatively regulated by PTPN2 in DNTs. (A and B) TNF-α mRNA and protein levels were analyzed by RT-PCR and ELISA, respectively. (C) The microglia were treated with CM from DNTs (with or without the PTPN2 inhibitor) for 24 h, followed by flow cytometry analysis of the percentage of CD86+ proinflammatory and CD206+ antiinflammatory microglia. n = 9 samples per group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the control group (microglia only); &&P < 0.01 compared with the DNT supernatant (without PTPN2 inhibition) group. The data are presented as the mean ± SD.